Neurorehabilitation News

A health innovations company has acquired a portfolio of electroencephalograph-related brain monitoring technologies and devices from an applied science firm to bolster its pipeline of products geared toward telehealth in neurology.

The European Commission has approved Hyqvia as maintenance therapy for individuals of all ages with chronic inflammatory demyelinating polyneuropathy.

The FDA has approved Gammagard Liquid as an IV immunoglobulin therapy to improve neuromuscular disability and impairment in adults with chronic inflammatory demyelinating polyneuropathy.

Isaac Health has raised $5.7 million to help identify and care for individuals with different cognitive and brain health conditions in the United States.

A biotechnology company has announced a partnership with a precision biomedicine firm to advance the use of electroencephalogram biomarkers across its clinical pipeline in neuropsychiatry and cognition.

A Houston-based neurohealth company has received a patent for its non-invasive, frequency-based deep brain stimulation device to address a range of psychiatric and neurologic conditions.

Health Canada has approved Uplizna as a monotherapy for adults with neuromyelitis optica spectrum disorder who are anti-aquaporin-4 immunoglobulin G seropositive.

In a cohort of older adults who smoked cannabis, impaired driving and elevated blood THC levels were significant 30 minutes after ingestion, according to research from JAMA Network Open.

A biopharma company has received approval from the European Medicines Agency to commence a phase 1 clinical trial of its selective endocannabinoid reuptake inhibitor, which aims to restore healthy brain physiology.

The FDA has approved expanded MRI labeling for Abbott’s dorsal root ganglion stimulation therapy, which allows those with complex regional pain syndrome to receive full-body MRI scans while implanted with the device.